How can a clinic market regenerative services to patients without making claims it cannot support?
Short answer
A clinic should describe the service, the provider and the visit, not what a product will do for a disease or condition. For a 361 HCT/P, homologous use is judged from the labeling, advertising and other indications of the manufacturer's objective intent, and the FTC expects health claims to rest on competent and reliable scientific evidence. Registration of a lab is not approval of its products, and federal rules require prior express written consent for certain telemarketing calls, so get advice before texting or calling a lead.
Why wording matters for a 361 HCT/P
One of the criteria in 21 CFR 1271.10(a) is that the HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent. FDA's guidance on minimal manipulation and homologous use (July 2020, FDA's current thinking, not binding) says objective intent can be shown by labeling claims, advertising, oral or written statements by the manufacturer or its representatives, and the circumstances in which an HCT/P is offered for a purpose for which it is neither labeled nor advertised.
So the way a product is described is part of whether it meets the criteria at all. FDA's consumer page on regenerative medicine therapies says unapproved products considered regenerative medicine therapies are often illegally marketed by clinics with claims about safety and effectiveness that have not been adequately studied. How a clinic's own wording bears on a particular product's status is a question for a healthcare attorney.
The FTC applies a separate test to all health advertising. Its Health Products Compliance Guidance (December 2022) says claims about the health benefits or safety of health related products require competent and reliable scientific evidence, and that a marketer is equally responsible for claims suggested or reasonably implied in an ad as for those stated outright.
Claims to leave out
These are working rules we suggest for every ad, page, post, script and message. They are not legal requirements in themselves:
- Do not say or imply that a product has any effect on a disease or condition.
- Do not say FDA has approved a product unless FDA's own list shows it, and do not suggest that registration with FDA means approval.
- Do not use "stem cell therapy" as the name of a service.
- Do not promise outcomes, results or timelines.
- Do not put a condition, symptom or body part next to a product name.
- Do not present results as scientifically established without the evidence the FTC expects.
The FTC guidance adds that marketers cannot suggest benefits indirectly that they could not claim directly, so a hint counts the same as a statement.
What a clinic can describe instead
These are things a clinic can describe without saying what a product does. They are not approved wording. Review all of it with counsel, including the word "regenerative" itself, which can imply an effect on the body:
- That the clinic offers a regenerative service line, and who it is for in plain, non medical terms.
- The consult or in person assessment: what happens at the visit, how long it takes and what it costs.
- The provider: name, license and role.
- The process: how to book, what to bring, and that suitability is decided at the visit.
- Where a patient can read FDA's own consumer information, such as its consumer page on regenerative medicine therapies.
Patient endorsements, before and after photos and reviews
The FTC's Endorsement Guides cover consumer endorsements in advertising. Under 16 CFR 255.2(a), an advertiser needs the same substantiation for claims made through consumer endorsements as for claims it makes directly, and consumer endorsements themselves are not competent and reliable scientific evidence. Under 16 CFR 255.2(b), an endorsement about a key attribute is likely to be read as what people will generally achieve, so without substantiation for that, the ad should clearly disclose the generally expected performance.
The FTC guidance puts it directly:
"Testimonials that report results more dramatic than users can generally expect are likely to be deceptive." FTC Health Products Compliance Guidance
One of the FTC guidance's own examples is an ad with before and after photographs and a fine print "These results are not typical" line, a disclosure the FTC says does not adequately tell consumers what they are likely to get. For reviews, 16 CFR 255.2(d) says advertisers should not procure, suppress, boost or edit consumer reviews in ways that distort what consumers think.
Registered is not approved
An FDA registration number says that an establishment registered. It does not say the product was reviewed. The regulation is explicit:
"FDA acceptance of an establishment registration and HCT/P listing form does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA." 21 CFR 1271.27(b)
FDA's consumer page adds that patients are sometimes told a product is registered with FDA to suggest it complies, and that registration and listing does not mean the product is legally marketed. The FTC guidance also warns advertisers not to mischaracterize the extent to which a product has been reviewed or authorized by FDA. More on product status is in What are the FDA 361 HCT/P criteria and what do they mean for clinics?
Consent for texts, calls and email
Federal rules on calls are in 47 CFR 64.1200. Paragraph (a)(2) bars telemarketing calls made with an autodialer or an artificial or prerecorded voice to wireless numbers and certain other lines unless the called party has given prior express written consent, and paragraph (f)(9) defines that consent as a written agreement, signed by the person, that clearly authorizes the seller to deliver such messages to a stated number. The same paragraph has exceptions, including one for certain health care messages.
The same section also covers text messages in one respect. Paragraph (a)(10) says a called party may revoke consent to calls or text messages made under paragraphs (a)(1) through (3) and (c)(2) by any reasonable method, that a reply of "stop", "quit", "end", "revoke", "opt out", "cancel" or "unsubscribe" to a text is a reasonable means in itself, and that revocation requests must be honored within a reasonable time not to exceed ten business days. Paragraph (a)(12) allows one confirmation text after a revocation, if it only confirms the request and carries no marketing.
Whether a particular text message needs prior express written consent under paragraph (a)(2), how the rules apply to a particular calling or texting system, and how the rules for email apply are questions for a telecommunications attorney. This guide does not answer them. Until you have that advice, collect consent in writing on the form a lead fills in, keep a record of the exact wording shown, and stop contacting anyone who asks you to.
A review routine before you publish
Before any ad, page, post or script goes out:
- Read it as a patient would. List every claim it states or implies.
- Remove anything that says or hints a product does something to a disease, condition, symptom or body part.
- Check every mention of FDA. Registration is not approval.
- Check that no endorsement, photo or review implies a typical result you cannot support.
- Check that the product is described within its labeling and stated uses.
- Confirm that consent is collected before any text or call.
- Have a healthcare attorney review it, and keep a dated copy of what was approved for release.
Sources
- 21 CFR 1271.10 and 21 CFR 1271.27, eCFR, read on 2026-11-20.
- FDA guidance: Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use, July 2020 (full text), read on 2026-11-20.
- FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies, content current as of 2024-04-08, read on 2026-11-20.
- FDA consumer alert on regenerative medicine products, dated July 22, 2020, read on 2026-11-20.
- FDA: list of approved cellular and gene therapy products, read on 2026-11-20.
- FTC: Health Products Compliance Guidance, December 2022, read on 2026-11-20.
- 16 CFR 255.2, FTC Endorsement Guides, consumer endorsements, eCFR, read on 2026-11-20.
- 47 CFR 64.1200, delivery restrictions on calls, eCFR, read on 2026-11-20.
Frequently asked questions
Can we say FDA has approved our regenerative product?
Only if FDA has in fact approved or licensed that specific product, which you can check against FDA's own list of approved cellular and gene therapy products. Meeting the criteria in 21 CFR 1271.10(a) does not mean FDA has approved a product. Under 21 CFR 1271.27(b), FDA's acceptance of an establishment registration and HCT/P listing is not a determination that the establishment complies with the rules or that the HCT/P is licensed or approved.
Can we use patient endorsements in our ads?
Under the FTC's Endorsement Guides, 16 CFR 255.2(a), an advertiser must have the same substantiation for claims made through consumer endorsements as for claims it makes directly, and consumer endorsements themselves are not competent and reliable scientific evidence. Under 16 CFR 255.2(b), an endorsement about a key attribute is likely to be read as typical. Review any patient endorsement with an attorney before it is published.
Can we name the conditions our patients come in with?
Be careful. For a 361 HCT/P, homologous use is judged from the labeling, advertising and other indications of the manufacturer's objective intent. FDA's guidance says that if an HCT/P "is intended for use as an unproven treatment for a myriad of diseases or conditions," it "is likely not intended for homologous use only." The FTC also holds advertisers responsible for implied claims. Ask a healthcare attorney before any material names a condition near a product or service.
Is "stem cell therapy" the same thing as a 361 HCT/P?
"Stem cell therapy" is not a regulatory category: it is not another name for a 361 HCT/P or for a 351 biological product. FDA's consumer alert says that, generally, all stem cell products require FDA approval. Whether any product is regulated solely under section 361 depends on whether it meets every criterion in 21 CFR 1271.10(a).
Does a disclaimer make a claim acceptable?
No. The FTC's Health Products Compliance Guidance says a disclaimer of the kind used on supplement labels won't fix an otherwise deceptive ad, and that a disclosure should not be contradicted or mitigated by anything else in the ad. It also says that adding a statement such as results not typical does not fix an endorsement that reports results more dramatic than users can generally expect.
Do we need consent before texting or calling a lead?
Get advice from a telecommunications attorney before you contact any lead. 47 CFR 64.1200(a)(2) bars telemarketing calls made with an autodialer or an artificial or prerecorded voice to wireless numbers and certain other lines unless the called party has given prior express written consent, which 64.1200(f)(9) defines as a signed written agreement. Collect and keep a record of consent before any text or call.